Drug Maker's Efforts to Compete in Lucrative Insulin Market Are Under Scrutiny

Avastin Shows Promise for Cancer Treatment, at a Price That Many Can't Pay ($100,000/yr)

New Drugs Hit the Market, but Promised Trials Go Undone

Where Has All the Prilosec Gone?

Pfizer Stirs Concern With Plans To Sell Heart Drugs Only as Pair

Private Health Care in Jails Can Be a Death Sentence

In City's Jails, Missed Signals Open Way to Season of Suicides

EPA Nominee Questioned about Low Income Families Paid $970 to Test Pesticides on Their Children

U.S. Marshals Seize 2 Drugs, Citing Production Violations

F.D.A. Nominee May Face Scrutiny of Tough Year and Tough Past

Marketing of Vioxx

Merck's Actions on Vioxx Face New Scrutiny

F.D.A. to Create Advisory Board on Drug Safety

Medical Panel Poses Pointed Questions to Drug Makers Over Risks of Painkillers

Merck May Resume Sales of Vioxx

F.D.A. Is Advised to Let Pain Pills Stay on Market

10 Voters on Panel Backing Pain Pills Had Industry Ties

Expert Kept From Speaking at Antidepressant Hearing

U.S. Won't Let Company Test All Its Cattle for Mad Cow

Making Drugs, Shaping the Rules

Bush's Aides Put Higher Price Tag on Medicare Law

The Medicare Index

Drug Sales Bring Huge Profits, and Scrutiny, to Cancer Doctors

Doctors Reap Millions for Anemia Drugs (EPO)

Celebrex Commercial, Long and Unconventional, Draws Criticism

H.P.V. Vaccine Furor

Merck to Halt Lobbying for Vaccine for Girls

Wall Street Finds a Lot to Like About Tobacco

F.D.A. Widens Safety Reviews on New Drugs

Psoriasis Drugs (Remicade) Hit a Cost Ceiling ($10,000-$35,000 per year)

Pfizer, Hurt by Rival Drugs, Will Lay Off 7,800

Editorial in Nature